Fulcrum Therapeutics, Inc.

By person

22 insiders · 98 transactions

1.0×

Alex C. Sapir holds only 1.0 times base salary in stock. $680.63K of shares against $650.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Alex C. Sapir last reported holding, valued at $3.52, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

$40.00M (8)

$58.38M (3)

−$18.38M

6,053,960

$21.31M

−57.1%

Gould Robert J

Director

—

$4.94M (29) scheduled

−$4.94M

454,864

$1.60M

−18.4%

Casdin Capital, LLC entity

10% owner

$2.22M (3)

—

+$2.22M

604,285

$2.13M

—

6 Dimensions Capital, L.P. entity

10% owner

$1.90M (1)

—

+$1.90M

559,821

$1.97M

—

Sanofi

10% owner

$1.50M (1)

—

+$1.50M

558,035

$1.96M

—

TANG KEVIN

10% owner

$1.49M (6)

—

+$1.49M

7,080,945

$24.92M

+6.3%

LEVIN MARK J

Director

$1.30M (1)

—

+$1.30M

9,924,404

$34.93M

+58.8%

Third Rock Ventures III, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

1,962,202

$6.91M

+586.8%

Third Rock Ventures IV, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

2,343,154

$8.25M

—

Stuart Bryan

See Remarks

—

$1.23M (2) scheduled

−$1.23M

$0.00

—

Moxham Christopher

Chief Scientific Officer

—

$911.42K (2) scheduled

−$911.42K

31,071

$109.37K

0.0%

Sapir Alex

See Remarks

$492.03K (1)

—

+$492.03K

193,360

$680.63K

—

Thomson Peter G.

VP Finance & Accounting

$20.70K (1)

$456.33K (8)

−$435.63K

17,512

$61.64K

−55.5%

Wallace Owen B.

Chief Scientific Officer

—

$245.44K (6) scheduled

−$245.44K

133,438

$469.70K

+5.0%

Cadavid Diego

SVP Clinical Development

—

$205.75K (13) scheduled

−$205.75K

65,714

$231.31K

−7.5%

GERAGHTY JAMES A

Director

$91.60K (1)

—

+$91.60K

90,714

$319.31K

+12.4%

Ezekowitz Alan

Director

—

$65.61K (1)

−$65.61K

10,927

$38.46K

−62.2%

Tourangeau Greg

Principal Accounting Officer

—

$62.26K (4)

−$62.26K

14,062

$49.50K

−15.5%

Oltmans Curtis Gale

Chief Legal Officer

$9.80K (1)

$44.60K (1)

−$34.80K

10,252

$36.09K

−18.7%

Morabito Christopher

Chief Medical Officer

$10.08K (1)

—

+$10.08K

1,100

$3.87K

—

GSK plc entity

10% owner

—

1,785,714

$6.29M

—

Section 32 Fund 2, LP entity

10% owner

—

464,285

$1.63M

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Fulcrum Therapeutics, Inc.

By person

Individual transactions

What was left out